

Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment: A prospective observational cohort study

KAMEN A TSVETANOV,^{1,2,*} LENNART R B SPINDLER,^{1,3} EMMANUEL A STAMATAKIS,^{1,3,4} VIRGINIA FJ NEWCOMBE,^{3,4} VICTORIA C LUPSON,^{3,4} DORIS A CHATFIELD,³ ANNE E MANKTELOW,³ JOANNE G OUTTRIM,³ ANNE ELMER,⁵ NATHALIE KINGSTON,^{6,7} JOHN R BRADLEY,^{7,8} EDWARD T BULLMORE,^{9,†} JAMES B ROWE,^{1,10,†} DAVID K MENON,^{3,4,5,†} AND THE CAMBRIDGE NEUROCOVID GROUP,^a THE NIHR COVID-19 BIORESOURCE,^b THE CAMBRIDGE NIHR CLINICAL RESEARCH FACILITY,^c AND THE CITIID-NIHR BIORESOURCE COVID-19 COLLABORATION^d

^a Cambridge NeuroCOVID Group: Anwar F, Allinson K, Bhatti J, Bullmore ET, Chatfield DA, Christmas D, Coles AJ, Coles JP, Correia M, Das T, Fletcher PC, Jubb AW, Lupson VC, Manktelow AE, Menon DK, Michell A, Needham EJ, Newcombe VFJ, Outtrim JG, Pointon L, Rodgers CT, Rowe JB, Rua C, Sithole N, Spindler LRB, Stamatakis EA, Taylor J, Valerio F, Widmer B, Williams GB.

^bNIHR COVID-19 BioResource⁶: Kingston N, Graves B, Le Gresley E, Caputo D, Stark H, Townsend P, Stirrups KE, Chinnery PF, Bradley JR.

^cNIHR Cambridge Clinical Research Facility: Saunders C, Elmer A

^d CITIID-NIHR BioResource COVID-19 collaboration: Baker S, Bradley JR, Dougan G, Hess C, Goodfellow I, Gupta R, Kingston N, Lehner PJ, Lyons PA, Matheson NJ, Oweland WH, Saunders C, Smith KGC, Summers C, Thaventhiran JED, Toshner M, Weekes MP.

* Corresponding author (kat35@cam.ac.uk, +44 1223 766 556)

† Equal contributions

¹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.

² Department of Psychology, University of Cambridge, Cambridge, UK.

³ Division of Anaesthesia, Department of Medicine, University Cambridge, Cambridge, UK.

⁴ Wolfson Brain Imaging Centre, University of Cambridge, Cambridge, UK.

⁵ Cambridge Clinical Research Centre, NIHR Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.

⁶ NIHR BioResource, Cambridge University Hospitals NHS Foundation, Cambridge Biomedical Campus, Cambridge, UK.

⁷ Department of Haematology, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

⁸ Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.

⁹ Department of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

¹⁰ Medical Research Council Cognition and Brain Sciences Unit, Department of Psychiatry, Cambridge, UK.

Abstract:

Human coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has multiple neurological consequences, but its long-term effect on brain health is still uncertain. The cerebrovascular consequences of COVID-19 may also affect brain health. Here we assess cerebrovascular health in 45 hospitalised patients using the resting state fluctuation amplitudes (RSFA) from functional magnetic resonance imaging, in relation to disease severity and in contrast with 42 controls. Widespread changes in frontoparietal RSFA were related to the severity of the acute COVID-19 episode, as indexed by COVID-19 WHO Progression Scale, inflammatory and coagulatory biomarkers. This relationship was not explained by chronic cardiorespiratory dysfunction, age, or sex. Exploratory analysis suggests that the level of cerebrovascular dysfunction is associated with cognitive, mental, and physical health at follow-up. The principal findings were consistent across univariate and multivariate approaches. The results indicate chronic cerebrovascular impairment following severe acute COVID-19, with the potential for long-term consequences on cognitive function and mental wellbeing.

Keywords (up to five): *cerebrovascular, microvascular, cardiorespiratory, neurology, COVID-19, SARS-CoV-2*

1. Introduction

2
3
4
5
6
7
8
9
10
11
12
13
14
15

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes human coronavirus disease 2019 (COVID-19) with multi-system effects that include neurological, vascular and neurovascular injury. Acute neurological sequelae are common, ranging from mild dizziness, headaches and anosmia to severe encephalitis, stroke and delirium (Chen et al., 2020; Hensley et al., 2021; Paterson et al., 2020; Zubair et al., 2020). These sequelae may arise from systemic physiological insults (e.g. hypoxia, hypotension, dysautonomia), coagulation dysfunction, large vessel occlusion, arterial stiffness, impaired vasoreactivity, neurotropic infection, parenchymal haemorrhage, or autoimmune responses against diverse antigens (Chen et al., 2020; Marcic et al., 2021; Mohkhedkar et al., 2021; Schnaubelt et al., 2021). Acute COVID-19 has also been associated with microvascular injury from vasculitis or endothelialitis (Becker, 2020; McGonagle et al., 2021), with endotheliopathy (Kakarla et al., 2021), vasogenic oedema and microthrombosis in the acute phase (Iba et al., 2020; Levi et al., 2020) and hypoperfusion in subacute phase (Hosp et al., 2021). While this acute pathophysiology is detectable using neuroimaging (Hanafi et al., 2020; Lersy et al., 2021; Newcombe

16 et al., 2020), the persistence and effects of cerebrovascular dysfunction over the medium- and long-
17 term remain unknown.

18

19 An important aspect of cerebrovascular function is the capacity of cerebral vessels to
20 constrict or dilate in response to physiological conditions such as alterations in carbon dioxide (CO₂)
21 and oxygen tension. This cerebrovascular reactivity (Willie et al., 2014) regulates regional blood flow
22 via pH-dependent modulation of vascular smooth muscle tone (Ainslie et al., 2005; Jensen et al.,
23 1988; Lambertsen et al., 1961; Lassen, 1968), but is compromised by arterial stiffness, compromised
24 endothelial function (Brandes et al., 2005), or disorders including hypertension, traumatic brain injury
25 and dementia. Poor cerebrovascular reactivity may also increase the risk of neurodegeneration (Gao
26 et al., 2013).

27

28 We therefore assessed the impact of COVID-19 on chronic cerebrovascular reactivity after
29 hospitalisation. We use a well-established non-invasive imaging method, exploiting naturally
30 occurring fluctuations in arterial CO₂ induced by variations in cardiac and respiratory cycles, which
31 moderate the blood oxygenation level-dependent (BOLD) signal underlying functional magnetic
32 resonance imaging (Birn et al., 2006; Glover et al., 2007). The BOLD signal variability at rest, known as
33 resting state fluctuation amplitudes (RSFA) is a safe, scalable and robust alternative to the gold
34 standard approaches (Kannurpatti and Biswal, 2008; Tsvetanov et al., 2020c, 2015). It is easier and
35 safer to apply in clinical cohorts than experimental hypercapnia, breath-holding and drug
36 interventions (Keyeux et al., 1995; Rostrup et al., 1996, 1994; Wagerle and Mishra, 1988). RSFA is
37 sensitive to cerebrovascular and cardiovascular differences in ageing (Garrett et al., 2017; Tsvetanov
38 et al., 2020b, 2015), small vessel disease (Makedonov et al., 2013), stroke (Nair et al., 2017; Raut et
39 al., 2016), Alzheimer's disease (Makedonov et al., 2016; Millar et al., 2020a), cognitive performance
40 (Liu et al., 2021; Millar et al., 2021, 2020b) and the presence of brain tumours (Agarwal et al., 2019,
41 2017).

42 We report on the chronic effect of COVID-19 on RSFA as a marker of cerebral microvascular
43 function, in relation to acute severity. Exploratory analyses examine the relationship to normative
44 regional variations in neurotransmitters/receptors, brain energy consumption and cell-type
45 distributions. Acute disease severity was quantified by the COVID-19 WHO Progression Scale and
46 blood biomarkers in patients hospitalised for COVID-19. We predicted that acute COVID-19 changes
47 regional RSFA at follow up, in proportion to acute disease severity, over and above the effects of
48 residual systemic cardiorespiratory impairment.

49 2. Methods

50

51 2.1. Participants

52 Patients were recruited through the NIHR COVID-19 BioResource, which received ethical
53 approval from East of England - Cambridge Central Research Ethics Committee (REC 17/EE/0025), and
54 provided written informed consent. Eligibility was based on admission to Addenbrookes Hospital with
55 COVID-19 between 10th March 2020 and 31st July 2020, aged 18 years or older, survived the acute
56 illness, and attended for a follow up visit, and no contradictions to MRI. 489 patients were potentially
57 eligible. Clinical data were obtained from inpatient electronic medical records, and from
58 cardiorespiratory and neurological assessment at follow-up clinical and research visits at least 6
59 weeks following symptom onset. 45 patients consented to participate, with clinical, structural and
60 functional resting state functional magnetic resonance imaging (fMRI) data of appropriate quality (see
61 below). Age and sex matched controls were scanned with the same sequences, with data pooled over
62 sequential cohorts to match demographics (Cambridgeshire Research Ethics Committee 97/290 and
63 REC 17/EE/0025, and Norfolk EE/0395 and a protocol approved by the Human Biology Ethics
64 Committee of the Council of the School of Biological Sciences, University of Cambridge). The study
65 and their processing pipelines are summarised in SI Figure 1.

66

67

68 2.2. Inpatient data: COVID-19 severity

69 The WHO COVID-19 11-point Progression scale was used to provide a measure of disease
70 severity with scores from 0 (non-infected) to 10 (dead) (see Figure 1 in Marshall et al., 2020). We also
71 used blood biomarkers previously associated with COVID-19 severity including the most extreme
72 values during hospitalisation on haematological (lowest platelets) (Wool and Miller, 2021),
73 inflammatory (C-reactive protein, CRP, serum ferritin) (Luan et al., 2021), immunological (interleukin-6,
74 IL-6) (Group et al., 2021a; Ulhaq and Soraya, 2020), hepatic (bilirubin) (Bangash et al., 2020) and
75 coagulatory (D-dimer, prothrombin time (PT) and activated partial thromboplastin time (APTT))
76 (Asakura and Ogawa, 2020; Iba et al., 2020; Levi et al., 2020). Details of laboratory assay methods
77 used are provided in the Supplementary section. All blood-based measurements were log-
78 transformed to transform the skewed data to approximately conform to normality. For consistency in
79 interpreting scores across blood samples, platelets values were inverted (iPlatelets) so that higher
80 scores represent lower count.

81

82 2.3. Clinical visit: cardiorespiratory assessment

83 Cardiorespiratory measurements were collected during a clinical assessment at least 12
84 weeks after discharge from initial hospitalization with COVID-19. Systolic and diastolic blood pressure
85 (BPS and BPD) were measured in lying (or seated) and standing position using automated
86 sphygmomanometry using GE Carescape V100 Dinamap Vital Signs Monitor (GE Healthcare Systems,
87 Chicago, Illinois, USA). We calculated pulse pressure (BPS-BPD) and orthostatic hypotension (e.g. BPS
88 lying – BPS standing). Lying and standing pulse pressure values were log-transformed to transform the
89 skewed data to approximately conform to normality.

90 Lung function was assessed via CareFusion Micro 1 Handheld Spirometer (Vyairre Medical
91 GmbH.; Hoechenberg, Germany) to determine peak expiratory flow (PEF), forced expiratory volume in
92 1 second (FEV1), forced vital capacity (FVC) and FEV1/FVC ratio. Measurements were repeated in
93 triplicate, with one minute rest between measurements. Each variable was log-transformed to
94 approximately conform to normality. To balance the representativeness of each data type in the
95 imputations and data-reduction stages (see Supplementary Method), spirometry measures were
96 reduced to a single variable using principal components analyses (SI Figure 2).

97 Pulse oximetry, monitored via GE Carescape V100 Dinamap Vital Signs Monitor (GE
98 Healthcare Systems, Chicago, Illinois, USA), was used to determine the heart rate and arterial oxygen
99 saturation before and following a 6-minute walk test (Bois et al., 2012; Crapo et al., 2012; PL et al.,
100 2003).

101
102

103 2.4. Research visit: neurological assessment

104 2.4.1. Image acquisition and pre-processing

105 Imaging data were acquired using a 3T Siemens Prismafit System with a 32-/20-channel head-
106 coil at the Wolfson Brain Imaging Centre (WBIC; www.wbic.cam.ac.uk) during a research visit. A 3D-
107 structural MRI was acquired on each participant using T1-weighted sequence (3D Magenitisation-
108 Prepared Rapid Gradient-Echo, 3D MPRAGE) with the following parameters: repetition time (TR) = 2
109 ms; echo time (TE) = 2.99 ms; inversion time (TI) = 880 ms; flip angle $\alpha = 9^\circ$; field of view (FOV) = 208 ×
110 256 × 256 mm³; resolution = 1 mm isotropic; accelerated factor (in-plane acceleration iPAT) = 2;
111 acquisition time, 5 min. T1 images were pre-processed using functions from SPM12 (Wellcome
112 Department of Imaging Neuroscience, London, UK) in Matlab 2020b (Mathworks,
113 <https://uk.mathworks.com/>). The T1 image was rigid-body coregistered to the MNI template, and
114 segmented to extract probabilistic maps of six tissue classes: gray matter (GM), white matter (WM),
115 CSF, bone, soft tissue, and residual noise.

116 RSFA was estimated from resting state Echo-Planar Imaging (EPI) of 477 volumes acquired
117 with 64 slices for whole brain coverage (TR = 735ms; TE = 30ms; FOV = 210mm x 210mm; resolution
118 = 2.38 x 2.38 x 2.4mm) during 5 minutes and 51 seconds. Participants were instructed to lay still, to
119 stay away and keep their eyes open, looking at a fixation cross. EPI data preprocessing included the
120 following steps: (1) temporal realignment of slices to (0,0,0) Montreal Neurological Institute (MNI) co-
121 ordinates, (2) spatial realignment to adjust for linear head motion, (3) subjected to Artifact detection
122 tools (ART)-based identification of outlier scans for scrubbing (4) coregistration to the T1 anatomical
123 image from above, (4) application of the normalization parameters from the T1 stream above to warp
124 the functional images into MNI space. We applied whole-brain independent component analysis of
125 sing-subject time series denoising to minimise motion artefacts using a priori heuristics using the ICA-
126 based Automatic Removal of Motion Artifact toolbox (AROMA; Pruim et al., 2015a, 2015b) after
127 smoothing with an 6mm FWHM Gaussian kernel.

128 The initial six volumes were discarded to allow for T1 equilibration. We quantified participant
129 motion using the root mean square volume-to-volume displacement as per Jenkinson et al (2002). A
130 general linear model (GLM) of the time-course of each voxel was used to further reduce the effects of
131 noise confounds (Geerligts et al., 2017), with linear trends and expansions of realignment parameters,
132 plus average signal in WM and CSF, CompCorr regressors, their derivative and quadratic regressors
133 (Satterthwaite et al., 2013). The WM and CSF signal was created by using the average across all voxels
134 with corresponding tissue probability larger than 0.7 in associated tissue probability maps available in
135 SPM12. A band-pass filter (0.0078-0.1 Hz) was implemented by including a discrete cosine transform
136 set in the GLM, ensuring that nuisance regression and filtering were performed simultaneously
137 (Hallquist et al., 2013; Lindquist et al., 2019). Finally, we calculated subject specific maps of RSFA
138 based on the normalized standard deviation across time for processed resting state fMRI time series
139 data (Tsvetanov et al., 2020b). RSFA maps were smoothed by a 12 mm FWHM Gaussian kernel.

140 To facilitate integrative multivariate analysis (see below), the RSFA maps were parcellated by
141 a prior cortical template into 360 bilaterally symmetric regions (Glasser et al., 2016). Regional RSFA
142 values were estimated by averaging over all voxels in each parcel.

143

144 2.4.2. Quality of life, cognition, and mental health

145 Quality of life, cognition and mental health were assessed using a set of questionnaires:
146 Generalised Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Patient Health
147 Questionnaire-15 (PHQ-15), Posttraumatic Stress Disorder Checklist-5 (PCL-5) and subscores from the
148 Short Form-36 (SF-36). SF36 subscores were defined as physical functioning (SF36-PF), role limitation

149 physical (SF36-RLP), role limitation emotional (SF36-RLE), energy dimension (SF36-ED), emotional
150 wellbeing (SF36-EW), social functioning (SF36-SF), pain (SF36-P) and general health (SF36-GH).

151

152 Cognitive function and functional independence were evaluated using Montreal Cognitive
153 Assessment (MoCA, Nasreddine et al., 2005), inverted Modified Ranking Scale (mRS, Eriksson et al.,
154 2007), and Barthel Index (BI, Mahoney and Barthel, 1965). For consistency in interpreting scores
155 across questionnaires, scores for mental health questionnaires were inverted (iGAD-7, iPHQ-9, iPHQ-
156 15 and iPCL-5) so that lower values represent greater mental health problems.

157 2.5. Analytical approach

158 Statistical analysis used Matlab 2020b calling the packages as described below. We
159 performed a descriptive analysis of all the characteristics from inpatient, clinical and cognitive data
160 before integrating it with neuroimaging data as described below.

161

162 2.5.1. Group differences in cerebral microvascular health

163 We performed component-based analysis, Source-Based Cerebrovasculometry
164 (Supplementary Material) to determine spatially non-overlapping RSFA maps without using group
165 information. Subject scores for each component was predicted by group identity (Patient vs Control),
166 age, and sex in a subsequence robust multiple linear regression. The model's formula was specified by
167 Wilkinson's notation, 'rsfa ~ group*age + sex' and fitted for each component separately.

168

169 2.5.2. COVID-19 severity predicting RSFA

170 The predictive specificity of COVID-19 severity on RSFA abnormality was tested using a
171 multivariate approach. We adopted a two-level procedure (Passamonti et al., 2019a; Tsvetanov et al.,
172 2020a, 2018, 2016). In the first-level analysis, the relationships between COVID-19 Severity and RSFA
173 data were identified using partial least squares (Krishnan et al., 2011). Partial least squares described
174 the linear relationship between the two multivariate data sets, namely RSFA maps and COVID-19
175 Severity data by providing pairs of latent variables (RSFA-LV) and (COVID-19 Severity-LV) as linear
176 combinations of the original variables that were optimized to maximize their covariance. Data set 1
177 consisted of parcellated RSFA maps across all patients (45 patients x 360 nodes array, RSFA dataset).
178 Data set 2 included the COVID-19 WHO Progression scale and inpatient blood data (45 subjects x 9
179 measures array, COVID-19 Severity datasets). All variables were z-scored (mean of 0 and standard
180 deviation of 1) before entering to a permutation-based PLS analysis with 10.000 permutations to
181 determine the significance of the latent variables.

182 Next, we tested whether the identified relationship between COVID-19 Severity-LV and RSFA-
183 LV could be explained by other variables of interest and variables of no interest. To this end, we
184 performed a second-level analysis using robust multiple linear regression and commonality analysis
185 (Kraha et al., 2012; Nimon et al., 2008a). Commonality analysis partitions the variance explained by all
186 predictors in MLR into variance unique to each predictor and variance shared between each
187 combination of predictors. Therefore, unique effects indicate the (orthogonal) variance explained by
188 one predictor over and above that explained by other predictors in the model, while common effects
189 indicate the variance shared between correlated predictors. Notably, the sum of variances, also
190 known as commonality coefficients, equals the total R² for the regression model. We adapted a
191 commonality analysis algorithm (Nimon et al., 2008b) implemented in Matlab (Wu et al., 2021). This
192 model aimed to test whether the relationship between COVID-19 Severity and RSFA can be explained
193 partly or fully by systemic cardiorespiratory dysfunction or other covariates of no interest. Predictor
194 variables included subject COVID-19 Severity scores from the first level PLS and systemic
195 cardiorespiratory dysfunction (CRDPC1 and CRDPC2). The dependent variable was subjects' RSFA
196 scores from the first level PLS. Covariates of no interest included age and sex. The model can
197 therefore identify unique variance explained by each of the predictors i.e. whether COVID-19 Severity
198 LV predicts RSFA-LV over and above other predictors. Common effects of interest were the
199 cardiorespiratory-related effects, defined by the common variance between COVID-19 Severity and
200 CRDPCA1-2. Significant effects of interest were identified with nonparametric testing using 10.000
201 permutations using commonality analysis implementation in Matlab (Wu et al., 2021).

202

203 2.5.3. Exploratory analysis

204 In an exploratory analysis, the level of RSFA abnormalities was related to component
205 measures of physical, cognitive, and mental functioning (PCM) using robust regression. The PCM
206 components, defined by principal component analysis (SI Methods), we defined as dependent
207 variables in separate models. RSFA, age and sex were entered as predictors. The model's formula was
208 specified by Wilkinson's notation, 'PCM ~ RSFA + age + sex' and fitted for each PCM component
209 separately.

210 We further assessed the spatial overlap between COVID-19-related cerebrovascular burden
211 maps and a range of brain metabolic, neurotransmitter, protein expression and cell-type parameters,
212 including i) existing receptor/metabolic templates and ii) gene transcription profiling maps. Templates
213 of interest included metabolic rates of glucose, oxygen, and aerobic glycolysis (Vaishnavi et al., 2010)
214 and receptor and transmitter maps across nine different neurotransmitter systems (Hansen et al.,
215 2021b), all measured by positron emission tomography (PET). Gene expression maps (Hawrylycz et

216 al., 2012) were based on key proteins implicated in SARS-Cov-2 cellular attachment (angiotensin
217 converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2), processing (cathepsin-B, CTSB;
218 cathepsin-L, CTSL) and viral defence (interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-
219 family member E, LY6E) (Iadecola et al., 2020; Yang et al., 2021). Spatial correlations were evaluated
220 using spin-based permutations preserving spatial autocorrelation (spin-permutation test) (Alexander-
221 Bloch et al., 2018; Fulcher et al., 2021).

222 Spatial covariance between the cerebrovascular burden map and gene expression across
223 9394 genes expressed in the human brain (Hawrylycz et al., 2012) was based on regularized-PLS
224 association (Blankertz et al., 2011; Ledoit and Wolf, 2004) using spin-premutation-based 10-fold
225 cross-validations (Tsvetanov et al., 2020a). The latent variable represented a spatial pattern of gene
226 expression that highly covaries with the cerebrovascular burden pattern associated with COVID-19
227 severity. Full details about the processed transcriptomic data are available elsewhere (Arnatkevičiūtė
228 et al., 2019). Genes highly expressing this pattern (i.e. high loadings) were tested against a molecular
229 atlas of human brain vasculature of 17 control and Alzheimer's disease patients (Yang et al., 2021)
230 using cell-type decomposition approach (Hansen et al., 2021a). This enabled us to test whether the
231 cerebrovascular burden-relevant genes are preferentially expressing in specific cell types i.e. testing
232 for cell-specific aggregate gene sets in eleven major canonical cortical cell classes: astrocytes (Astro);
233 brain endothelial cells (BEC); ependymal (Epend); macrophage/microglia (MacMic); meningeal
234 fibroblast (MFibro); neuron (Neuro); oligodendrocyte precursors (Opc); oligodendrocytes (Oligo);
235 pericytes (Peri); perivascular fibroblast (PFibro); smooth muscle cells (SMC). To this end, we calculated
236 the ratio of genes in each set preferentially expressed in each cell type (e.g. ratio for pericytes is
237 calculated from the number of genes preferentially expressed in pericytes divided by the total
238 number of genes). Gene sets were thresholded to include the top $n\%$ of genes with greatest loadings,
239 where n varied from 5% to no threshold. Statistical significance was determined using a null
240 distribution of ratios based on 10.000 sets of random genes (Hansen et al., 2021a).

241

242 2.6. Data availability and code

243

244 Code and composite data to reproduce manuscript figures, statistical analyses are available at
245 https://github.com/kamentsvetanov/covid19_cerebrovascularburden. Resting-state fMRI data was
246 pre-processed using SPM12 (<http://www.fil.ion.ucl.ac.uk/spm/>; Friston et al., 2007) and post-
247 processed using a GLM-like approach (Geerligts et al., 2017) available at [https://github.com/MRC-](https://github.com/MRC-CBU/riksneurotools/blob/master/GLM/)
248 [CBU/riksneurotools/blob/master/GLM/](https://github.com/MRC-CBU/riksneurotools/blob/master/GLM/). MATLAB-based commonality analysis for neuroimaging is
249 available at <https://github.com/kamentsvetanov/CommonalityAnalysis/>. Visualisation of

250 neuroimaging results was in MRICroGL (<https://github.com/rordenlab/MRICroGL>; Rorden and Brett,
251 2000) and BrainSpace (Vos de Wael et al., 2020). Neurotransmitter receptor and transporter maps
252 were available at https://github.com/netneurolab/hansen_receptors. Spin permutations (Váša et al.,
253 2018) used code available at https://github.com/frantisekvasa/rotate_parcellation. Fully-pre-
254 processed transcriptomic data was available at
255 <https://figshare.com/articles/dataset/AHBAdata/6852911> and
256 <https://github.com/BMHLab/AHBAProcessing>. The molecular atlas of the human brain vasculature
257 was available at <https://www.biorxiv.org/content/10.1101/2021.04.26.441262v1>. Cell-type
258 decomposition analysis related code was available at
259 https://github.com/netneurolab/hansen_genescognition.
260

261 3. Results

262 3.1. Participants

263 Characteristics of the 45 patients hospitalized with COVID-19 are detailed in Table 1. At
 264 hospitalisation, 30% of the patients required a mechanical ventilation (n=13) for an average of 20
 265 days; 22% of patients required vasopressors (n=10), and 9% renal replacement therapy with
 266 continuous veno-venous haemodiafiltration (n=4). The average number of days from initial symptoms
 267 to clinical and research visit was 169±35 and 180±58, respectively. Data missingness is detailed in
 268 Supplementary Results.

269

270 *Table 1. Characteristics of 45 patients hospitalised with COVID-19. n - indicates number of patients and the*
 271 *percentage of patients from the patient cohort (%), SD – standard deviation, IQR – interquartile range, kg – weight in*
 272 *kilograms, m – height in meters.*

Variable	n (%)	Mean(SD)/Median(IQR)*
Age (years)	45 (100)	52 (14)
Education (years)	45 (100)	16 (4)
Female	26 (58)	-
Right-handed	40 (89)	-
Inpatient data		
Vasopressors	10 (22)	-
Dialysis	4 (9)	-
BMI (kg/m ²)	36 (80)	29 (4)
Mechanical Ventilation (days)	13 (29)	20 (15)
CRP	42 (93)	149 (147)
D Dimer	37 (82)	1125 (2071)
Ferritin	32 (71)	1225 (1700)
IL-6	28 (62)	39 (80)
PT	32 (71)	26 (54)
APTT	33 (73)	42 (36)
Bilirubin	43 (96)	14 (8)
Platelets	44 (98)	230 (102)
Clinical Visit		
HR (bpm)	38 (84)	76 (14)
RR (cpm)	38 (84)	16 (2)
SBP lying (mmHg)	38 (84)	134 (23)
SBP standing (mmHg)	33 (73)	130 (20)
DBP lying (mmHg)	38 (84)	74 (12)
DBP standing (mmHg)	33 (73)	79 (11)
Research Visit		
GAD-7 (0-21)	44 (98)	4 (8)*
PHQ-9 (0-27)	44 (98)	7 (9)*
PHHQ-15 (0-30)	39 (87)	9 (8)*
PCL-5 (0-80)	44 (98)	16 (22)*
MoCA	39 (87)	28 (3)*
mRS	39 (87)	1 (1)*
BI	37 (82)	20 (0)*
Initial symptoms to Admission (days)	40 (89)	14 (14)
Hospitalisation Duration (days)	40 (89)	19 (31)
Initial symptoms to Clinic visit (days)	39 (87)	169 (35)
Initial symptoms to Research visit (days)	45 (100)	180 (58)

273


274

275 3.2. Group differences in Cerebrovascular components

276 Using source-based cerebrovasculometry (Passamonti et al., 2019b; Tsvetanov et al., 2020b,
277 2015; Xu et al., 2009), we assessed the group differences in RSFA-based cerebrovascular components
278 between controls and patients in small set of spatially independent components (n=8). Each
279 participant had one value per component, *subject score*, indicating the degree to which a participant
280 expresses the spatial map of the corresponding component. One component showed significant
281 difference between the patient and control group in terms of subject scores (RSFA_{IC4}, $t = 3.12$, p
282 $= 0.003$, Figure 1), while controlling for age and sex in a robust linear regression. The spatial extent of
283 this component, RSFA_{IC4}, included voxels with high values in temporo-parietal regions, indicating that
284 individuals with higher loading values, in this case the patient group, had lower RSFA values in these
285 regions, relative to the control group (Figure 1). The other components did not differentiate patients
286 from controls (SI Analyses).

287 The spatial pattern of IC4 was consistent with the univariate approach ($r=0.46$, $p<0.001$, SI
288 Figure 5). In addition, the univariate approach revealed that the spatial pattern in RSFA associated
289 with age was highly consistent with the one reported on large-scale population-based cohorts, $r=0.42$,
290 $p<0.001$ (Tsvetanov et al., 2020b, 2015). This suggests that RSFA can detect reliably differences in
291 cerebrovascular health across various phenotypes in smaller samples. Though age is a risk factor of
292 COVID-19 severity (Verity et al., 2020) and RSFA (Tsvetanov et al., 2020c), the COVID-19 group effect
293 was not explained by individual's age, and showed only a partial overlap with the effects of age on
294 RSFA in parietal regions (SI Figure 5, Tsvetanov et al., 2020b, 2015).

295



296

297 *Figure 1. Source-based cerebrovasculometry for the component differentially expressed between groups: (left)*
298 *independent component spatial map reflecting decrease in RSFA values in temporo-parietal regions. (right) Bar plot of subject*
299 *scores for patients hospitalised for COVID-19 (red) and control group (green, each circle represents an individual) indicating*
300 *higher loading values for patients than controls as informed by two-sample unpaired permutation test (a robust regression*
301 *was used to down-weight the effects of extreme data points)*

302

3.3. COVID-19 Severity predicts cerebrovascular impairment

Using PLS analysis, we identified one significant pair of latent variables ($r = 0.584$, $p = 0.017$, based on a null distribution of 10,000 permutations). Variable loadings and subject scores showed a strong relationship between acute COVID-19 Severity and chronic RSFA abnormalities (Figure 2).

The RSFA latent variable (RSFA-LV) expressed negative loadings in frontal (superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus and portions of the anterior cingulate) and parieto-temporal (angular gyrus, supramarginal gyrus, superior temporal gyrus, middle temporal gyrus) regions. This pattern of COVID-19 Severity-related reduction in RSFA values was mirrored in a voxel-wise analysis of RSFA maps and COVID-19 Severity component (SI Figure 5). Positive loadings in the RSFA data appeared to be in postcentral gyrus, calcarine sulcus, cuneus, and lingual gyrus. Increase in the RSFA signal in these regions may reflect increased pulsatility in neighbouring vascular and white matter territories (see SI Figure 5) as reported previously (Makedonov et al., 2016, 2013; Tsvetanov et al., 2020b, 2015). This pair of latent variables suggested that patients with higher COVID-19 Severity at acute stage have poorer cerebrovascular function in frontal and temporo-parietal regions at chronic stage. For visualisation purposes we inverted the loading values in Figure 2a so that higher values reflect poorer cerebrovascular function, i.e. higher cerebrovascular burden.




Figure 2. Partial least squares analysis of COVID-19 severity data at acute stage and RSFA-based cerebrovascular burden (CVB) at chronic stage. (panel a) Spatial distribution of parcellated RSFA values where dark to light colours are used for the strength of positive and negative correlations with the COVID-19 Severity profile (panel c). Note that regions with high cerebrovascular burden have low values in RSFA. The scatter plot in the middle panel represents the relationship between subjects scores of RSFA-latent variable and COVID-19 Severity-latent variable identified by partial least squares analysis.

To understand whether the relationship between regional RSFA impairment and COVID-19 Severity can be explained by chronic systemic cardiorespiratory dysfunction (see SI method) or covariates of no interest, we performed a second level robust regression analysis. RSFA-LV was entered as the dependent variable. COVID-19 Severity LV and the cardiorespiratory dysfunction

333 component (CRD_{PCA1} , see SI Figure 3) were entered as predictors, while age and sex were modelled as
334 covariates of no interest. All variables were normalised to have a mean of 0 and standard deviation 1.
335 Using Wilkinson notation, the regression model took the form: $RSFA-LV \sim COVID-19\ Severity-LV +$
336 $CRD_{PCA1} + CRD_{PCA2} + Age + Sex$. COVID-19 Severity was the only significant predictor of RSFA-LV in the
337 model ($r = 0.471$, $p = 0.001$ and SI Table 1), suggesting that chronic cardiorespiratory dysfunction, age
338 and sex cannot explain fully the relationship between COVID-19 Severity and RSFA abnormality.
339 Interestingly, the unique variance explained by COVID-19 Severity in the regression model was weaker
340 than the variance identified by the PLS analysis ($r = 0.584$ vs $r=0.471$ for PLS and MLR analyses)
341 suggesting that one or more of the predictors in the model explain partly some of the variance
342 between COVID-19 Severity and RSFA. Permutation-based commonality analysis with 10.000
343 permutations (SI Method) confirmed that a portion of the variance between COVID-19 Severity-LV
344 and RSFA-LV was explained by age (12% total, $p < 0.001$), cardiorespiratory dysfunction component 2
345 (CRD_{PC2} , 3% total, $p = 0.009$), and shared variance between age and cardiorespiratory dysfunction
346 component 1 (Age, CRD_{PCA1} , 20% total, $p < 0.001$), SI Table 2. COVID-19 Severity-LV remained as the
347 largest unique predictor of RSFA-LV (37% total, $p=0.006$).

348


349 3.4. Exploratory analysis

350 The level of RSFA abnormalities (RSFA-LV) was related to physical, cognitive and mental
351 functioning in an exploratory analysis. RSFA-LV, age and sex were entered as predictors, while
352 cognitive and mental health components (SI Methods) were used as dependent variables in separate
353 robust regressions (Model 1: $CMH_{PCA1} \sim RSFA-LV + age + sex$; Model 2: $CMH_{PCA2} \sim RSFA-LV + age +$
354 sex). Model 1 was not significant ($p = 0.429$), while Model 2 was significant ($R^2 = 0.294$, $p = 0.002$)
355 with RSFA predicting significantly cognitive and mental health component 2 ($r = -0.352$, $p = 0.014$, SI
356 Table 3). This indicates that patients with higher RSFA abnormality have worse cognitive function, less
357 functional independence and lower quality of life (social functioning, emotional wellbeing, energy
358 dimension). The results did not change in a meaningful way by re-imputing the data ($n=5$). The
359 findings in Model 2 were confirmed using voxel-wise analysis on RSFA maps, instead of RSFA-LV (SI
360 Figure 7).

361 We next assessed the spatial overlap between COVID-19-related cerebrovascular burden maps with
362 existing neurotransmitter and metabolic maps using spatial autocorrelation-preserving permutation
363 testing (Alexander-Bloch et al., 2018). Across 21 candidate maps, we show that the cerebrovascular
364 burden map overlaps with the distribution of serotonin's vasoactive receptor 5-HT1b, aerobic
365 glycolysis and to a weaker extent cerebral metabolic rate of glucose in the brain. However, the

366 regional distribution of RSFA abnormality showed little correlation with the expression of key proteins
 367 implicated in SARS-CoV-2 cellular attachment, processing and viral defence (Figure 3). Collectively,
 368 these results demonstrate that the distribution of cerebrovascular impairment related to COVID-19
 369 severity is aligned with the spatial distribution of receptors and processes involved in the coordination
 370 of metabolic and vasoreactive responses.

371
 372




373
 374 *Figure 3. Spatial correlation between Covid19 severity-induced cerebrovascular burden map and spatial patterns*
 375 *associated with a range of neurotransmitter receptor/transporters (Hansen et al., 2021b), selective genes relevant to SARS-*
 376 *CoV-2 brain entry (Iadecola et al., 2020) and brain metabolism parameters (Vaishnavi et al., 2010). Neurotransmitter*
 377 *receptors and transporters were selective to serotonin (5-HT1a, 5-HT1b, 5-HT2a, 5-HT4, 5-HT6, 5-HTT), norepinephrine (NET),*
 378 *histamine (H3), acetylcholine (ACh, A4B2, M1, VAcHT), cannabinoid (CB1), opioid (MOR), glutamate (mGluR5), GABA*
 379 *(GABAa/bz) and dopamine (D1, D2, DAT). Metabolic maps were based on cerebral blood flow (CBF), cerebral blood volume*
 380 *(CBV), cerebral metabolic rate of glucose and oxygen (CMRglu, CMRO2) and glycemic index (GI). Selective genes relevant to*
 381 *SARS-CoV-2 brain entry included angiotensin converting enzyme-2, ACE2; neuropilin-1, NRP1; neuropilin-2, NRP2, cathepsin-*
 382 *B, CTSB; cathepsin-L, CTSL, interferon type 2 receptors, IFNAR2; lymphocyte antigen 6-family member E, LY6E. The spatial*
 383 *maps of 5-HT1b, CMRglu and Glycemic Index (GI) were significantly correlated with Covid19 severity-induced cerebrovascular*
 384 *burden map (* p-spin<0.05 (one-sided), *** p-spin<0.001). See text for more information.*

385
 386 As a final step, we used normative transcriptomics to identify genes that are normally
 387 preferentially expressed in the regions associated with COVID-19-induced cerebrovascular
 388 impairment. Regularised-PLS identified one latent component ($r=.64, p=0.001$, Figure 4a). Using cell-
 389 type decomposition analysis on a vascular cell-type specific gene sets, we determined the ratio of
 390 genes in each gene set preferentially expressed in one of eleven cortical cell types: astrocytes, brain


endothelial cells, ependymal, macrophage/microglia, meningeal fibroblast, neuron, oligodendrocyte precursors, oligodendrocytes, pericytes, perivascular fibroblast, smooth muscle cells. Gene-sets were thresholded to include the top 70% of genes with the highest loadings (Figure 4b), noting that results are consistent across thresholds ranging from 5 to no threshold (Supplementary Figure 8). Dominant genes were significantly more expressed in pericytes, brain endothelial cells and neurons, and significantly less expressed in oligodendrocytes. Broadly, we find evidence that areas associated with cerebrovascular impairment are enriched in for genetic signal related to neuron support (pericytes, endothelial cells and perineuronal oligodendrocytes) and neurons themselves. This dichotomy is consistent with the observations from the spatial overlap analysis.

400

a | CVB-related transcription map



b | cell-specific expression



401

402 *Figure 4. a, Spatial map in the transcriptome data related to the COVID-19-induced cerebrovascular burden map*
403 *(CVB). b, Cell-type decomposition was used to identify cell-type enrichment based on extent to which genes expressed the*
404 *transcriptome map in a. Gene sets for each cell-type was constructed by thresholding the top 70% of genes with greatest*
405 *loadings. Note that results were consistent across a range of thresholds, ranging from 10% to no threshold, SI Figure 8. The*
406 *ratio of genes in each gene set preferentially expressed in eleven distinct cell-types (circles) is shown against their null*
407 *distribution of a model with random selection of all genes (10,000 permutations, *p-value < 0.05). For example, pericyte's*
408 *ratio is calculated from the number of genes preferentially expressed in pericytes divided by the total number of genes. Cell*
409 *type-specificity of genes is described elsewhere (Yang et al., 2021) Astro – astrocytes, BEC – brain endothelial cells, Epend –*
410 *ependymal, MacMic – macrophage/microglia, Mfibo – meningeal fibroblast, Neuron – neuron, OPC – oligodendrocyte*
411 *precursor cells, Oligo – oligodendrocytes, Peri – pericytes, Pfibro – perivascular fibroblast, SMC – smooth muscle cells*

412

413 4. Discussion

414

415 We show that abnormalities in cerebral microvascular function, measured using resting state
416 fluctuation amplitudes (RSFA), persist many months after hospitalisation for acute COVID-19. The
417 location of these abnormalities in lateral frontal and temporoparietal regions aligns partly with
418 cerebrovascular dysfunction reported in association with ageing (Tsvetanov et al., 2020b, 2015),
419 preclinical Alzheimer's disease (Millar et al., 2020a) and systemic cardiovascular health (Tsvetanov et

420 al., 2020b). These post-COVID-19 effects were observed over and above age. They are related to
421 severity of the acute illness and the host response in the acute stage. These effects also relate to the
422 post-COVID-19 cognitive function, common indices of mental health, and quality of life at an average
423 of six months after hospitalisation.

424 In exploratory analysis, we found overlap between the regional distribution of this
425 cerebrovascular impairment and spatial distribution of the vasoreactive receptor 5-HT_{1b} and regions
426 with high metabolic demands. 5-HT_{1b} receptor is the dominant contractile 5-HT receptor in cerebral
427 arteries (Barnes et al., 2021; Nilsson et al., 1999), acting on vasoconstriction by contracting smooth
428 muscle endothelial smooth muscle directly or as moderator of other vasoconstrictors. Distinct from
429 its effects on vascular tone, the presynaptic 5-HT_{1b} receptor also has an important microvascular
430 anti-inflammatory role, both in the cerebrovascular bed and more generally. Further, its loss has
431 been implicated in progressive cognitive loss and abnormal modulation through descending
432 serotonergic outputs (Gharishvandi et al., 2020; Heijmans et al., 2021; Mitsikostas et al., 2002;
433 Sibille et al., 2007), which may be relevant for late sequelae after COVID-19.

434 The overlap of cerebrovascular impairment with the regional distribution of aerobic glycolysis
435 and glucose metabolism is spatially concordant with previous reports of hypometabolism in the
436 subacute phase of COVID-19 (Hosp et al., 2021) and neurodegeneration (Vlassenko et al., 2010). This
437 discussion provides a potential link between cerebrovascular impairment and metabolic dysfunction
438 in frontoparietal regions, which could provide important insights regarding the mechanisms of late
439 neurocognitive dysfunction following COVID-19 infection. Future work should establish whether
440 changes to the microvasculature lead to hypometabolism (Shi et al., 2016) or the vulnerability of brain
441 physiology in chronic phase is due to hypoxic and hypometabolic exposure in the subacute phase
442 (Vestergaard et al., 2020). Collectively, these results demonstrate that the distribution of chronic
443 cerebrovascular impairment related to COVID-19 severity maps to the spatial distribution of
444 processes involved in coordinating metabolic and vasoregulatory responses associated with changes
445 in brain function and cognition.

446 We also tested whether genes highly expressed in regions with COVID-19-induced cerebrovascular
447 change are preferentially expressed in specific cell types using a molecular atlas of human brain
448 vasculature (Yang et al., 2021). Dominant genes were overexpressed in pericytes, brain endothelial
449 cells and neurons, but underexpressed in oligodendrocytes. The evidence that genes implicated are
450 enriched in pericytes and endothelial cells is particularly interesting. Brain endothelial cells are
451 susceptible to direct SARS-CoV-2 infection through flow-dependent expression of ACE2. The SARS-

452 CoV-2 S protein binding triggers a gene expression profile that may compromise the neurovascular
453 interface (Kaneko et al., 2021). On the abluminal aspect of the neurovascular interface, pericytes
454 express abundantly the angiotensin-converting enzyme-2 (ACE2) receptor (He et al., 2020). The
455 expression can be increased with by exposure to the viral S protein, and importantly, potentiated in
456 combination with hypoxia (Khaddaj-Mallat et al., 2021), a mechanism which could account for the
457 modulation of RSFA abnormality by disease severity in our cohort.

458 Given this biological context the correlation of RSFA abnormalities with disease severity is
459 open to two potential interpretations. One possibility is that these changes in cerebrovascular
460 regulatory integrity are the consequence of direct viral invasion; while the other is that these
461 abnormalities are a consequence of the inflammatory host response, which is a consequence of, but
462 may not scale precisely with, viral infection. Spatial correlation of RSFA abnormality with the
463 expression of ACE2 and Neuropilin-1, or of genes involved in cellular responses to viral invasion would
464 have provided supportive evidence of a role for direct viral infection as a mechanism, but we were
465 unable to demonstrate such a correlation. This negative finding favours the explanation that host
466 inflammatory responses may be drivers in this context, and merit further investigation as mechanisms
467 of late cerebrovascular regulatory dysfunction. It is important to acknowledge that our correlations
468 with regional gene expression are based on expression patterns in normal brain, and that these
469 expression patterns may be substantially altered by the inflammatory milieu that prevails in the
470 context of COVID-19. Consequently, direct examination gene expression patterns in late COVID-19
471 survivors would provide additional insights.

472

473 Our study has several limitations. We are limited by the relatively small sample size, and by
474 the absence of longitudinal imaging data. We also do not draw any causal inferences from the
475 associations we observe. However, the demonstration of functional microvascular abnormalities
476 following COVID-19 is important to understand the potential mechanisms of persistent cognitive and
477 mental health problems. The association of microvascular abnormalities with late outcomes of
478 relevance to patients, and the fact that they represent an easily accessible biomarker, suggest both a
479 potential therapeutic target and/or a biomarker of treatment effect in interventional studies. It
480 remains to be shown whether the localisation of RSFA abnormalities to regions rich in 5HT-1b
481 receptors is a consequence of overactivity of these receptors (resulting in low cerebral blood flow),
482 underactivity or loss of these receptors (resulting in vasoparalysis and/or inflammation), or a
483 manifestation of flow-metabolism mismatching with inadequate substrate and oxygen delivery. This is
484 relevant as potential therapeutic agents that are available to modulate both 5HT-1b function (Barnes
485 et al 2021) and inflammatory response (Zhang et al., 2020) (Group et al., 2021b; Zhang et al., 2020).

486

487 In summary, we demonstrate that the severity of acute COVID-19 predicts cerebrovascular
488 impairment six months later. The cerebrovascular abnormality was associated with worse cognitive
489 function, mental health, functional recovery, and quality of life months after hospitalisation. Localised
490 across lateral frontotemporoparietal regions, we show that its genetic signature shapes the
491 composition of cell-types and metabolism. Collectively, these results implicate the COVID-19-related
492 vulnerability of brain systems differentially relying on diverse physiology and cell biology in support of
493 their functional specialisation.

494

495 5. Acknowledgements

496

497 This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014),
498 NIHR funding to the NIHR BioResource (RG94028 & RG85445), Guarantors of Brain (G101149),
499 Wellcome Trust (220258), Medical Research Council (SUAG/051G101400; and SUAG/010 RG91365),
500 and by the Addenbrookes Charitable Trust. We thank NIHR BioResource volunteers for their
501 participation, and gratefully acknowledge NIHR BioResource centres, NHS Trusts and staff for their
502 contribution. We thank the National Institute for Health Research, NHS Blood and Transplant, and
503 Health Data Research UK as part of the Digital Innovation Hub Programme. The views expressed are
504 those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health
505 and Social Care.

506

507

508

509

510 6. Conflicts of interest

511 All authors have no conflicts of interest. Untreated to this there are several disclosures.

512

513 VFJN holds a grant from Roche Pharmaceuticals on proteomic biomarkers in traumatic brain injury
514 and reports personal fees from Neurodiem.

515

516 ETB serves on the scientific advisory board of Sosei Hepatares and as a consultant for GSK.

517

518 JBR serves as an associate editor to Brain and is a non-remunerated trustee of the Guarantors of
519 Brain, Darwin College and the PSP Association (UK). He provides consultancy to Asceneuron, Biogen,
520 UCB and has research grants from AZ-Medimmune, Janssen, and Lilly as industry partners in the
521 Dementias Platform UK.

522

523 DKM reports grants, personal fees, and nonfinancial support from GlaxoSmithKline Ltd.; grants,
524 personal fees, and other from NeuroTrauma Sciences; grants and personal fees from Integra Life
525 Sciences; personal fees from Pfizer Ltd.; grants and personal fees from Lantmannen AB; from Calico
526 Ltd.; personal fees from Pressura Neuro Ltd.; and others from Cortirio Ltd., outside the submitted
527 work.

528

529 7. References

530

531 Agarwal, S., Hanzhang, L., Pillai, J.J., 2017. Value of Frequency Domain Resting-State Functional
532 Magnetic Resonance Imaging Metrics Amplitude of Low-Frequency Fluctuation and Fractional
533 Amplitude of Low-Frequency Fluctuation in the Assessment of Brain Tumor-Induced
534 Neurovascular Uncoupling. <https://home.liebertpub.com/brain> 7, 382–389.
535 <https://doi.org/10.1089/BRAIN.2016.0480>

536 Agarwal, S., Sair, H., Gujar, S., Hua, J., Lu, H., Pillai, J., 2019. Functional Magnetic Resonance Imaging
537 Activation Optimization in the Setting of Brain Tumor-Induced Neurovascular Uncoupling Using
538 Resting-State Blood Oxygen Level-Dependent Amplitude of Low Frequency Fluctuations. *Brain*
539 connectivity 9, 241–250. <https://doi.org/10.1089/BRAIN.2017.0562>

540 Ainslie, P.N., Ashmead, J.C., Ide, K., Morgan, B.J., Poulin, M.J., 2005. Differential responses to CO₂ and
541 sympathetic stimulation in the cerebral and femoral circulations in humans. *The Journal of*
542 *physiology* 566, 613–24. <https://doi.org/10.1113/jphysiol.2005.087320>

543 Alexander-Bloch, A.F., Shou, H., Liu, S., Satterthwaite, T.D., Glahn, D.C., Shinohara, R.T., Vandekar,
544 S.N., Raznahan, A., 2018. On testing for spatial correspondence between maps of human brain
545 structure and function. *NeuroImage* 178, 540.
546 <https://doi.org/10.1016/J.NEUROIMAGE.2018.05.070>

547 Arnatkevičiūtė, A., Fulcher, B.D., Fornito, A., 2019. A practical guide to linking brain-wide gene
548 expression and neuroimaging data. *NeuroImage* 189, 353–367.
549 <https://doi.org/10.1016/J.NEUROIMAGE.2019.01.011>

- 550 Asakura, H., Ogawa, H., 2020. COVID-19-associated coagulopathy and disseminated intravascular
551 coagulation. *International Journal of Hematology* 2020 113:1 113, 45–57.
552 <https://doi.org/10.1007/S12185-020-03029-Y>
- 553 Bangash, M.N., Patel, J., Parekh, D., 2020. COVID-19 and the liver: little cause for concern. *The Lancet*
554 *Gastroenterology & Hepatology* 5, 529–530. [https://doi.org/10.1016/S2468-1253\(20\)30084-4](https://doi.org/10.1016/S2468-1253(20)30084-4)
- 555 Barnes, N.M., Ahern, G.P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S.,
556 Cunningham, K.A., Fone, K.C., Gershon, M., di Giovanni, G., Goodfellow, N.M., Halberstadt, A.L.,
557 Hartley, R.M., Hassaine, G., Herrick-Davis, K., Hovius, R., Lacivita, E., Lambe, E.K., Leopoldo, M.,
558 Levy, F.O., Lummis, S.C.R., Marin, P., Maroteaux, L., McCreary, A.C., Nelson, D.L., Neumaier, J.F.,
559 Newman-Tancredi, A., Nury, H., Roberts, A., Roth, B.L., Roumier, A., Sanger, G.J., Teitler, M.,
560 Sharp, T., Villalón, C.M., Vogel, H., Watts, S.W., Hoyer, D., 2021. International Union of Basic and
561 Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology
562 and Function. *Pharmacological reviews* 73, 310–520. <https://doi.org/10.1124/PR.118.015552>
- 563 Becker, R.C., 2020. COVID-19-associated vasculitis and vasculopathy. *Journal of Thrombosis and*
564 *Thrombolysis* 2020 50:3 50, 499–511. <https://doi.org/10.1007/S11239-020-02230-4>
- 565 Birn, R.M., Diamond, J.B., Smith, M. a, Bandettini, P. a, 2006. Separating respiratory-variation-related
566 fluctuations from neuronal-activity-related fluctuations in fMRI. *NeuroImage* 31, 1536–48.
567 <https://doi.org/10.1016/j.neuroimage.2006.02.048>
- 568 Blankertz, B., Lemm, S., Treder, M., Haufe, S., Müller, K.-R., 2011. Single-trial analysis and classification
569 of ERP components--a tutorial. *NeuroImage* 56, 814–25.
570 <https://doi.org/10.1016/j.neuroimage.2010.06.048>
- 571 Bois, R.M. du, Weycker, D., Albera, C., Bradford, W.Z., Costabel, U., Kartashov, A., Lancaster, L., Noble,
572 P.W., Sahn, S.A., Szwarcborg, J., Thomeer, M., Valeyre, D., Talmadge E. King, Jr., 2012. Six-
573 Minute-Walk Test in Idiopathic Pulmonary Fibrosis. [https://doi.org/10.1164/rccm.201007-](https://doi.org/10.1164/rccm.201007-1179OC)
574 [1179OC](https://doi.org/10.1164/RCCM.201007-1179OC) 183, 1231–1237. <https://doi.org/10.1164/RCCM.201007-1179OC>
- 575 Brandes, R.P., Fleming, I., Busse, R., 2005. Endothelial aging. *Cardiovascular Research*.
576 <https://doi.org/10.1016/j.cardiores.2004.12.027>
- 577 Chen, X., Laurent, S., Onur, O.A., Kleineberg, N.N., Fink, G.R., Schweitzer, F., Warnke, C., 2020. A
578 systematic review of neurological symptoms and complications of COVID-19. *Journal of*
579 *Neurology* 2020 268:2 268, 392–402. <https://doi.org/10.1007/S00415-020-10067-3>
- 580 Crapo, R.O., Casaburi, R., Coates, A.L., Enright, P.L., MacIntyre, N.R., McKay, R.T., Johnson, D., Wanger,
581 J.S., Zeballos, R.J., Bittner, V., Mottram, C., 2012. ATS Statement: Guidelines for the six-minute
582 walk test. <https://doi.org/10.1164/ajrccm.166.1.at1102> 166, 111–117.
583 <https://doi.org/10.1164/AJRCCM.166.1.AT1102>

- 584 Eriksson, M., Appelros, P., Norrving, B., Terént, A., Stegmayr, B., 2007. Assessment of Functional
585 Outcome in a National Quality Register for Acute Stroke. *Stroke* 38, 1384–1386.
586 <https://doi.org/10.1161/01.STR.0000260102.97954.9C>
- 587 Friston, K.J., Ashburner, J., Kiebel, S., Nichols, T., Penny, W.D., 2007. Statistical parametric mapping :
588 the analysis of functional brain images. Elsevier Academic Press. [https://doi.org/10.1016/B978-0-](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)
589 [12-372560-8.X5000-1](https://doi.org/10.1016/B978-0-12-372560-8.X5000-1)
- 590 Fulcher, B.D., Arnatkeviciute, A., Fornito, A., 2021. Overcoming false-positive gene-category
591 enrichment in the analysis of spatially resolved transcriptomic brain atlas data. *Nature*
592 *Communications* 2021 12:1 12, 1–13. <https://doi.org/10.1038/s41467-021-22862-1>
- 593 Gao, Y.-Z., Zhang, J.-J., Liu, H., Wu, G.-Y., Xiong, L., Shu, M., 2013. Regional cerebral blood flow and
594 cerebrovascular reactivity in Alzheimer’s disease and vascular dementia assessed by arterial
595 spinlabeling magnetic resonance imaging. *Current neurovascular research* 10, 49–53.
- 596 Garrett, D.D., Lindenberger, U., Hoge, R.D., Gauthier, C.J., 2017. Age differences in brain signal
597 variability are robust to multiple vascular controls. *Scientific Reports* 7, 10149.
598 <https://doi.org/10.1038/s41598-017-09752-7>
- 599 Geerligs, L., Tsvetanov, K.A., Cam-Can, Henson, R.N., 2017. Challenges in measuring individual
600 differences in functional connectivity using fMRI: The case of healthy aging. *Human Brain*
601 *Mapping*. <https://doi.org/10.1002/hbm.23653>
- 602 Gharishvandi, F., Abdollahi, A., Shafaroodi, H., Mohammad Jafari, R., Pasalar, P., Dehpour, A.R., 2020.
603 Involvement of 5-HT1B/1D receptors in the inflammatory response and oxidative stress in
604 intestinal ischemia/reperfusion in rats. *European journal of pharmacology* 882.
605 <https://doi.org/10.1016/J.EJPHAR.2020.173265>
- 606 Glasser, M.F., Coalson, T.S., Robinson, E.C., Hacker, C.D., Harwell, J., Yacoub, E., Ugurbil, K.,
607 Andersson, J., Beckmann, C.F., Jenkinson, M., Smith, S.M., Van Essen, D.C., 2016. A multi-modal
608 parcellation of human cerebral cortex. *Nature* 2016 536:7615 536, 171–178.
609 <https://doi.org/10.1038/nature18933>
- 610 Glover, G.H., Shmueli, K., van Gelderen, P., de Zwart, J. a, Horovitz, S.G., Fukunaga, M., Jansma, J.M.,
611 Duyn, J.H., 2007. Low-frequency fluctuations in the cardiac rate as a source of variance in the
612 resting-state fMRI BOLD signal. *NeuroImage* 38, 306–20.
613 <https://doi.org/10.1016/j.neuroimage.2007.07.037>
- 614 Group, T.W.R.E.A. for C.-19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M.,
615 Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E.,
616 Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J.,
617 Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J.,

618 Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci,
619 A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M.,
620 Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols,
621 H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, A.-K.,
622 Aleman, S., Sönnernborg, A., Henter, J.-I., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi,
623 Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng,
624 A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R.,
625 Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D.,
626 McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R.,
627 Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A.,
628 Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K.,
629 Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M.,
630 Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L.,
631 Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,
632 Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte,
633 Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C.,
634 SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G.,
635 BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G.,
636 AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE,
637 L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA,
638 O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G.,
639 SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O.,
640 Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J.,
641 Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F.,
642 Pourchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S.,
643 Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes,
644 R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A.,
645 Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L.,
646 Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L.,
647 Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M.,
648 Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N.,
649 Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H.,
650 Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S.,
651 Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO,

652 J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C.,
653 Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J.,
654 Strek, M., Adegunsoye, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B.,
655 Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F.,
656 Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B.,
657 Colman, R., Buysier, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T.,
658 Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby,
659 P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E.,
660 Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A.,
661 Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers,
662 A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohhahn,
663 G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van,
664 Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021a.
665 Association Between Administration of IL-6 Antagonists and Mortality Among Patients
666 Hospitalized for COVID-19: A Meta-analysis. JAMA 326, 499–518.
667 <https://doi.org/10.1001/JAMA.2021.11330>
668 Group, T.W.R.E.A. for C.-19 T. (REACT) W., Domingo, P., Mur, I., Mateo, G.M., Gutierrez, M. del M.,
669 Pomar, V., Benito, N. de, Corbacho, N., Herrera, S., Millan, L., Muñoz, J., Malouf, J., Molas, M.E.,
670 Asensi, V., Horcajada, J.P., Estrada, V., Gutierrez, F., Torres, F., Perez-Molina, J.A., Fortun, J.,
671 Villar, L.M., Hohenthal, U., Marttila, H., Vuorinen, T., Nordberg, M., Valtonen, M., Frigault, M.J.,
672 Mansour, M.K., Patel, N.J., Fernandes, A., Harvey, L., Foulkes, A.S., Healy, B.C., Shah, R., Bensaci,
673 A.M., Woolley, A.E., Nikiforow, S., Lin, N., Sagar, M., Shrager, H., Huckins, D.S., Axelrod, M.,
674 Pincus, M.D., Fleisher, J., Lampa, J., Nowak, P., Vesterbacka, J.C., Rasmuson, J., Skorup, P., Janols,
675 H., Niward, K.F., Chatzidionysiou, K., Asgeirsson, H., Parke, Å., Blennow, O., Svensson, A.-K.,
676 Aleman, S., Sönerborg, A., Henter, J.-I., Horne, A.C., Al-Beidh, F., Angus, D., Annane, D., Arabi,
677 Y., Beane, A., Berry, S., Bhimani, Z., Bonten, M., Bradbury, C., Brunkhorst, F., Buxton, M., Cheng,
678 A., Cove, M., Jong, M. de, Derde, L., Estcourt, L., Goossens, H., Gordon, A., Green, C., Haniffa, R.,
679 Ichihara, N., Lamontagne, F., Lawler, P., Litton, E., Marshall, J., McArthur, C., McAuley, D.,
680 McGuinness, S., McVerry, B., Montgomery, S., Mouncey, P., Murthy, S., Nichol, A., Parke, R.,
681 Parker, J., Reyes, F., Rowan, K., Saito, H., Santos, M., Seymour, C., Shankar-Hari, M., Turgeon, A.,
682 Turner, A., Bentum-Puijk, W. van, Veerdonk, F. van de, Webb, S., Zarychanski, R., Baillie, J.K.,
683 Beasley, R., Cooper, N., Fowler, R., Galea, J., Hills, T., King, A., Morpeth, S., Netea, M.,
684 Ogungbenro, K., Pettila, V., Tong, S., Uyeki, T., Youngstein, T., Higgins, A., Lorenzi, E., Berry, L.,
685 Salama, C., Rosas, I.O., Ruiz-Antorán, B., Rubio, E.M., Martínez, A.R., Esteban, J.C., Solá, C.A.,

686 Pizov, R., Sanz, J.S., Abad-Santos, F., Bautista-Hernández, A., García-Fraile, L., Barrios, A., Liarte,
687 Á.G., Pérez, T.A., Rodríguez-García, S.C., Mejía-Abril, G., Prieto, J.C., Leon, R., VEIGA, V.C.,
688 SCHEINBERG, P., FARIAS, D.L.C., PRATS, J.G., CAVALCANTI, A.B., MACHADO, F.R., ROSA, R.G.,
689 BERWANGER, O., AZEVEDO, L.C.P., LOPES, R.D., DOURADO, L.K., CASTRO, C.G., ZAMPIERI, F.G.,
690 AVEZUM, A., LISBOA, T.C., ROJAS, S.S.O., COELHO, J.C., LEITE, R.T., CARVALHO, J.C., ANDRADE,
691 L.E.C., SANDES, A.R., PINTÃO, M.C.T., SANTOS, S. v., ALMEIDA, T.M.L., COSTA, A.N., GEBARA,
692 O.C.E., FREITAS, F.G.R., PACHECO, E.S., MACHADO, D.J.B., MARTIN, J., CONCEIÇÃO, F.G.,
693 SIQUEIRA, S.R.R., DAMIANI, L.P., ISHIHARA, L.M., SCHNEIDER, D., SOUZA, D. de, Hermine, O.,
694 Mariette, X., Tharaux, P.L., Rigon, M.R., Porcher, R., Ravaud, P., Azoulay, E., Cadranel, J.,
695 Emmerich, J., Fartoukh, M., Guidet, B., Humbert, M., Lacombe, K., Mahevas, M., Pene, F.,
696 Pouchet-Martinez, V., Schlemmer, F., Tibi, A., Yazdanpanah, Y., Dougados, M., Bureau, S.,
697 Horby, P.W., Landray, M.J., Baillie, K.J., Buch, M.H., Chappell, L.C., Day, J.N., Faust, S.N., Haynes,
698 R., Jaki, T., Jeffery, K., Juszczak, E., Lim, W.S., Mafham, M., Montgomery, A., Mumford, A.,
699 Thwaites, G., Kamarulzaman, A., Omar, S.F.S., Ponnampalavanar, S., Azwa, R.I.S.R., Wong, P.L.,
700 Kukreja, A., Ong, H.C., Sulaiman, H., Basri, S., Ng, R.X., Johari, B.M., Rajasuriar, R., Chong, M.L.,
701 Neelamegam, M., Mansor, S.M.S., Zulhaimi, N.S., Lee, C.S., Altice, F., Price, C., Malinis, M.,
702 Hasan, M.S., Wong, C.K., Chidambaram, S., Misnan, N.A., Thabit, A.A.M., Sim, B., Bidin, F.N.,
703 Rahim, M.A.H.M.A., Saravanamuttu, S., Tuang, W.X., Gani, Y.M., Thangavelu, S., Tay, K.H.,
704 Ibrahim, N.M., Halid, L.A., Tan, K.T., Mukri, M.N.A., Arip, M., Koh, H.M., Badaruddin, S.N.A.S.,
705 Sureja, L.R., Chun, G.Y., TORRE-CISNEROS, J., MERCHANTE, N., LEON, R., CARCEL, S., GARRIDO,
706 J.C., Galun, E., Soriano, A., Martínez, J.A., Castán, C., Paredes, R., Dalmau, D., Carbonell, C.,
707 Espinosa, G., Castro, P., Muñóz, J., Almuedo, A., Prieto, S., Pacheco, I., Ratain, M., Pisano, J.,
708 Strek, M., Adegunsoye, A., Karrison, T., Jozefien, D., F.A., V.D.K., Elisabeth, D.L., Cedric, B.,
709 Bastiaan, M., Shankar-Hari, M., Vale, C.L., Godolphin, P.J., Fisher, D., Higgins, J.P.T., Spiga, F.,
710 Savović, J., Tierney, J., Baron, G., Benbenishty, J.S., Berry, L.R., Broman, N., Cavalcanti, A.B.,
711 Colman, R., Buysier, S.L. de, Derde, L.P.G., Domingo, P., Omar, S.F., Fernandez-Cruz, A., Feuth, T.,
712 Garcia, F., Garcia-Vicuna, R., Gonzalez-Alvaro, I., Gordon, A.C., Haynes, R., Hermine, O., Horby,
713 P.W., Horick, N.K., Kumar, K., Lambrecht, B.N., Landray, M.J., Leal, L., Lederer, D.J., Lorenzi, E.,
714 Mariette, X., Merchante, N., Misnan, N.A., Mohan, S. v., Nivens, M.C., Oksi, J., Perez-Molina, J.A.,
715 Pizov, R., Porcher, R., Postma, S., Rajasuriar, R., Ramanan, A. v., Ravaud, P., Reid, P.D., Rutgers,
716 A., Sancho-Lopez, A., Seto, T.B., Sivapalasingam, S., Soin, A.S., Staplin, N., Stone, J.H., Strohhahn,
717 G.W., Sunden-Cullberg, J., Torre-Cisneros, J., Tsai, L.W., Hoogstraten, H. van, Meerten, T. van,
718 Veiga, V.C., Westerweel, P.E., Murthy, S., Diaz, J. v., Marshall, J.C., Sterne, J.A.C., 2021b.
719 Association Between Administration of IL-6 Antagonists and Mortality Among Patients

- 720 Hospitalized for COVID-19: A Meta-analysis. *JAMA* 326, 499–518.
721 <https://doi.org/10.1001/JAMA.2021.11330>
- 722 Hallquist, M.N., Hwang, K., Luna, B., 2013. The nuisance of nuisance regression: spectral
723 misspecification in a common approach to resting-state fMRI preprocessing reintroduces noise
724 and obscures functional connectivity. *NeuroImage* 82, 208–25.
725 <https://doi.org/10.1016/j.neuroimage.2013.05.116>
- 726 Hanafi, R., Roger, P.-A., Perin, B., Kuchcinski, G., Deleval, N., Dallery, F., Michel, D., Hacein-Bey, L.,
727 Pruvo, J.-P., Outteryck, O., Constans, J.-M., 2020. COVID-19 Neurologic Complication with CNS
728 Vasculitis-Like Pattern. *American Journal of Neuroradiology* 41, 1384–1387.
729 <https://doi.org/10.3174/AJNR.A6651>
- 730 Hansen, J.Y., Markello, R.D., Vogel, J.W., Seidlitz, J., Bzdok, D., Masic, B., 2021a. Mapping gene
731 transcription and neurocognition across human neocortex. *Nature Human Behaviour* 2021 5:9 5,
732 1240–1250. <https://doi.org/10.1038/s41562-021-01082-z>
- 733 Hansen, J.Y., Shafiei, G., Markello, R.D., Smart, K., Cox, S.M.L., Wu, Y., Gallezot, J.-D., Aumont, É.,
734 Servaes, S., Scala, S.G., DuBois, J.M., Wainstein, G., Bezgin, G., Funck, T., Schmitz, T.W., Spreng,
735 R.N., Soucy, J.-P., Baillet, S., Guimond, S., Hietala, J., Bédard, M.-A., Leyton, M., Kobayashi, E.,
736 Rosa-Neto, P., Palomero-Gallagher, N., Shine, J.M., Carson, R.E., Tuominen, L., Dagher, A., Masic,
737 B., 2021b. Mapping neurotransmitter systems to the structural and functional organization of
738 the human neocortex. *bioRxiv* 2021.10.28.466336. <https://doi.org/10.1101/2021.10.28.466336>
- 739 Hawrylycz, M.J., Lein, E.S., Guillozet-Bongaarts, A.L., Shen, E.H., Ng, L., Miller, J.A., van de Lagemaat,
740 L.N., Smith, K.A., Ebbert, A., Riley, Z.L., Abajian, C., Beckmann, C.F., Bernard, A., Bertagnolli, D.,
741 Boe, A.F., Cartagena, P.M., Mallar Chakravarty, M., Chapin, M., Chong, J., Dalley, R.A., Daly, B.D.,
742 Dang, C., Datta, S., Dee, N., Dolbeare, T.A., Faber, V., Feng, D., Fowler, D.R., Goldy, J., Gregor,
743 B.W., Haradon, Z., Haynor, D.R., Hohmann, J.G., Horvath, S., Howard, R.E., Jeromin, A., Jochim,
744 J.M., Kinnunen, M., Lau, C., Lazarz, E.T., Lee, C., Lemon, T.A., Li, L., Li, Y., Morris, J.A., Overly, C.C.,
745 Parker, P.D., Parry, S.E., Reding, M., Royall, J.J., Schulkin, J., Sequeira, P.A., Slaughterbeck, C.R.,
746 Smith, S.C., Sodt, A.J., Sunkin, S.M., Swanson, B.E., Vawter, M.P., Williams, D., Wohnoutka, P.,
747 Ronald Zielke, H., Geschwind, D.H., Hof, P.R., Smith, S.M., Koch, C., Grant, S.G.N., Jones, A.R.,
748 2012. An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature*
749 489, 391–399. <https://doi.org/10.1038/NATURE11405>
- 750 He, L., Mäe, M.A., Muhl, L., Sun, Y., Pietilä, R., Nahar, K., Liébanas, E.V., Fagerlund, M.J., Oldner, A.,
751 Liu, J., Genové, G., Zhang, L., Xie, Y., Leptidis, S., Mocci, G., Stritt, S., Osman, A., Anisimov, A.,
752 Hemanthakumar, K.A., Räsänen, M., Mirabeau, O., Hansson, E., Björkegren, J., Vanlandewijck,
753 M., Blomgren, K., Mäkinen, T., Peng, X.R., Arnold, T.D., Alitalo, K., Eriksson, L.I., Lendahl, U.,

- 754 Betsholtz, C., 2020. Pericyte-specific vascular expression of SARS-CoV-2 receptor ACE2 –
755 implications for microvascular inflammation and hypercoagulopathy in COVID-19. bioRxiv
756 2020.05.11.088500. <https://doi.org/10.1101/2020.05.11.088500>
- 757 Heijmans, L., Mons, M.R., Joosten, E.A., 2021. A systematic review on descending serotonergic
758 projections and modulation of spinal nociception in chronic neuropathic pain and after spinal
759 cord stimulation. *Molecular pain* 17. <https://doi.org/10.1177/17448069211043965>
- 760 Hensley, M.K., Markantone, D., Prescott, H.C., 2021. Neurologic Manifestations and Complications of
761 COVID-19. <https://doi.org/10.1146/annurev-med-042320-010427> 73.
762 <https://doi.org/10.1146/ANNUREV-MED-042320-010427>
- 763 Hosp, J., Dressing, A., Blazhenets, G., Bormann, T., Rau, A., Schwabenland, M., Thurow, J., Wagner, D.,
764 Waller, C., Niesen, W., Frings, L., Urbach, H., Prinz, M., Weiller, C., Schroeter, N., Meyer, P.,
765 2021. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of
766 COVID-19. *Brain : a journal of neurology* 144, 1263–1276.
767 <https://doi.org/10.1093/BRAIN/AWAB009>
- 768 Iadecola, C., Anrather, J., Kamel, H., 2020. Effects of COVID-19 on the Nervous System. *Cell* 183, 16.
769 <https://doi.org/10.1016/J.CELL.2020.08.028>
- 770 Iba, T., Connors, J.M., Levy, J.H., 2020. The coagulopathy, endotheliopathy, and vasculitis of COVID-
771 19. *Inflammation Research* 2020 69:12 69, 1181–1189. [https://doi.org/10.1007/S00011-020-](https://doi.org/10.1007/S00011-020-01401-6)
772 [01401-6](https://doi.org/10.1007/S00011-020-01401-6)
- 773 Jenkinson, M., Bannister, P., Brady, M., Smith, S., 2002. Improved optimization for the robust and
774 accurate linear registration and motion correction of brain images. *NeuroImage* 17, 825–41.
- 775 Jensen, K.E., Thomsen, C., Henriksen, O., 1988. In vivo measurement of intracellular pH in human
776 brain during different tensions of carbon dioxide in arterial blood. A ³¹P-NMR study. *Acta*
777 *physiologica Scandinavica* 134, 295–8. <https://doi.org/10.1111/j.1748-1716.1988.tb08492.x>
- 778 Kakarla, V., Kaneko, N., Nour, M., Khatibi, K., Elahi, F., Liebeskind, D.S., Hinman, J.D., 2021.
779 Pathophysiologic mechanisms of cerebral endotheliopathy and stroke due to Sars-CoV-2:
780 <https://doi.org/10.1177/0271678X20985666> 41, 1179–1192.
781 <https://doi.org/10.1177/0271678X20985666>
- 782 Kaneko, N., Satta, S., Komuro, Y., Muthukrishnan, S.D., Kakarla, V., Guo, L., An, J., Elahi, F., Kornblum,
783 H.I., Liebeskind, D.S., Hsiai, T., Hinman, J.D., 2021. Flow-Mediated Susceptibility and Molecular
784 Response of Cerebral Endothelia to SARS-CoV-2 Infection. *Stroke* 260–270.
785 <https://doi.org/10.1161/STROKEAHA.120.032764>

- 786 Kannurpatti, S.S., Biswal, B.B., 2008. Detection and scaling of task-induced fMRI-BOLD response using
787 resting state fluctuations. *NeuroImage* 40, 1567–74.
788 <https://doi.org/10.1016/j.neuroimage.2007.09.040>
- 789 Keyeux, A., Ochrymowicz-Bemelmans, D., Charlier, A.A., 1995. Induced response to hypercapnia in the
790 two-compartment total cerebral blood volume: influence on brain vascular reserve and flow
791 efficiency. *Journal of cerebral blood flow and metabolism : official journal of the International*
792 *Society of Cerebral Blood Flow and Metabolism* 15, 1121–31.
793 <https://doi.org/10.1038/jcbfm.1995.139>
- 794 Khaddaj-Mallat, R., Aldib, N., Bernard, M., Paquette, A.-S., Ferreira, A., Lecordier, S., Saghatelian, A.,
795 Flamand, L., ElAli, A., 2021. SARS-CoV-2 deregulates the vascular and immune functions of brain
796 pericytes via Spike protein. *Neurobiology of Disease* 161, 105561.
797 <https://doi.org/10.1016/J.NBD.2021.105561>
- 798 Kraha, A., Turner, H., Nimon, K., Zientek, L.R., Henson, R.K., 2012. Tools to Support Interpreting
799 Multiple Regression in the Face of Multicollinearity. *Frontiers in Psychology* 3, 44.
800 <https://doi.org/10.3389/fpsyg.2012.00044>
- 801 Krishnan, A., Williams, L.J., McIntosh, A.R., Abdi, H., 2011. Partial Least Squares (PLS) methods for
802 neuroimaging: A tutorial and review. *NeuroImage* 56, 455–475.
803 <https://doi.org/10.1016/j.neuroimage.2010.07.034>
- 804 Lambertsen, C.J., Semple, S.J.G., Smyth, M.G., Gelfand, R., 1961. H⁺ and pCO₂ as chemical factors in
805 respiratory and cerebral circulatory control. *Journal of Applied Physiology* 16, 473–484.
806 <https://doi.org/10.1152/jappl.1961.16.3.473>
- 807 Lassen, N.A., 1968. Brain extracellular pH: the main factor controlling cerebral blood flow.
808 *Scandinavian journal of clinical and laboratory investigation* 22, 247–51.
809 <https://doi.org/10.3109/00365516809167060>
- 810 Ledoit, O., Wolf, M., 2004. A well-conditioned estimator for large-dimensional covariance matrices.
811 *Journal of Multivariate Analysis* 88, 365–411. [https://doi.org/10.1016/S0047-259X\(03\)00096-4](https://doi.org/10.1016/S0047-259X(03)00096-4)
- 812 Lersy, F., Anheim, M., Willaume, T., Chammas, A., Brisset, J.-C., Ois Cotton, F., Kremer, S., 2021.
813 Cerebral vasculitis of medium-sized vessels as a possible mechanism of brain damage in COVID-
814 19 patients. *Journal of Neuroradiology* 48, 141–146.
815 <https://doi.org/10.1016/j.neurad.2020.11.004>
- 816 Levi, M., Thachil, J., Iba, T., Levy, J.H., 2020. Coagulation abnormalities and thrombosis in patients
817 with COVID-19. *The Lancet Haematology* 7, e438–e440. [https://doi.org/10.1016/S2352-](https://doi.org/10.1016/S2352-3026(20)30145-9)
818 [3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)

- 819 Lindquist, M.A., Geuter, S., Wager, T.D., Caffo, B.S., 2019. Modular preprocessing pipelines can
820 reintroduce artifacts into fMRI data. *Human Brain Mapping* 40, 2358–2376.
821 <https://doi.org/10.1002/hbm.24528>
- 822 Liu, X., Tyler, L.K., Cam-CAN, Rowe, J.B., Tsvetanov, K.A., 2021. Multimodal fusion analysis of
823 functional, cerebrovascular and structural neuroimaging in healthy ageing subjects. *bioRxiv*
824 2021.12.22.473894. <https://doi.org/10.1101/2021.12.22.473894>
- 825 Luan, Y.Y., Yin, C.H., Yao, Y.M., 2021. Update Advances on C-Reactive Protein in COVID-19 and Other
826 Viral Infections. *Frontiers in Immunology* 12, 3153.
827 <https://doi.org/10.3389/FIMMU.2021.720363/BIBTEX>
- 828 Mahoney, F.I., Barthel, D.W., 1965. Barthel Index. *Maryland State Medical Journal* 61–65.
- 829 Makedonov, I., Black, S.E., Macintosh, B.J., 2013. BOLD fMRI in the white matter as a marker of aging
830 and small vessel disease. *PloS one* 8, e67652. <https://doi.org/10.1371/journal.pone.0067652>
- 831 Makedonov, I., Chen, J.J., Masellis, M., MacIntosh, B.J., 2016. Physiological fluctuations in white
832 matter are increased in Alzheimer’s disease and correlate with neuroimaging and cognitive
833 biomarkers. *Neurobiology of Aging* 37, 12–18.
834 <https://doi.org/10.1016/j.neurobiolaging.2015.09.010>
- 835 Marcic, M., Marcic, L., Marcic, B., Capkun, V., Vukojevic, K., 2021. Cerebral Vasoreactivity Evaluated by
836 Transcranial Color Doppler and Breath-Holding Test in Patients after SARS-CoV-2 Infection.
837 *Journal of personalized medicine* 11. <https://doi.org/10.3390/JPM11050379>
- 838 Marshall, J.C., Murthy, S., Diaz, J., Adhikari, N.K., Angus, D.C., Arabi, Y.M., Baillie, K., Bauer, M., Berry,
839 S., Blackwood, B., Bonten, M., Bozza, F., Brunkhorst, F., Cheng, A., Clarke, M., Dat, V.Q., Jong, M.
840 de, Denholm, J., Derde, L., Dunning, J., Feng, X., Fletcher, T., Foster, N., Fowler, R., Gobat, N.,
841 Gomersall, C., Gordon, A., Glueck, T., Harhay, M., Hodgson, C., Horby, P., Kim, Y., Kojan, R.,
842 Kumar, B., Laffey, J., Malvey, D., Martin-Loeches, I., McArthur, C., McAuley, D., McBride, S.,
843 McGuinness, S., Merson, L., Morpeth, S., Needham, D., Netea, M., Oh, M.-D., Phyu, S., Piva, S.,
844 Qiu, R., Salisu-Kabara, H., Shi, L., Shimizu, N., Sinclair, J., Tong, S., Turgeon, A., Uyeki, T.,
845 Veerdonk, F. van de, Webb, S., Williamson, P., Wolf, T., Zhang, J., 2020. A minimal common
846 outcome measure set for COVID-19 clinical research. *The Lancet Infectious Diseases* 20, e192–
847 e197. [https://doi.org/10.1016/S1473-3099\(20\)30483-7](https://doi.org/10.1016/S1473-3099(20)30483-7)
- 848 McGonagle, D., Bridgewood, C., Ramanan, A. V., Meaney, J.F.M., Watad, A., 2021. COVID-19 vasculitis
849 and novel vasculitis mimics. *The Lancet. Rheumatology* 3, e224. [https://doi.org/10.1016/S2665-9913\(20\)30420-3](https://doi.org/10.1016/S2665-9913(20)30420-3)
- 851 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Fagan, A.M., Morris, J.C., Balota, D.A., 2020a.
852 Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer’s

- 853 disease. *Neurobiology of Aging* 96, 233–245.
- 854 <https://doi.org/10.1016/J.NEUROBIOLAGING.2020.08.007>
- 855 Millar, P.R., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A., 2021. Evaluating
- 856 Cognitive Relationships with Resting-State and Task-driven Blood Oxygen Level-Dependent
- 857 Variability. *Journal of cognitive neuroscience* 33, 279–302.
- 858 https://doi.org/10.1162/JOCN_A_01645
- 859 Millar, P.R., Petersen, S.E., Ances, B.M., Gordon, B.A., Benzinger, T.L.S., Morris, J.C., Balota, D.A.,
- 860 2020b. Evaluating the Sensitivity of Resting-State BOLD Variability to Age and Cognition after
- 861 Controlling for Motion and Cardiovascular Influences: A Network-Based Approach. *Cerebral*
- 862 *Cortex* 00, 1–16. <https://doi.org/10.1093/cercor/bhaa138>
- 863 Mitsikostas, D.D., Sanchez Del Rio, M., Waeber, C., 2002. 5-Hydroxytryptamine(1B/1D) and 5-
- 864 hydroxytryptamine1F receptors inhibit capsaicin-induced c-fos immunoreactivity within mouse
- 865 trigeminal nucleus caudalis. *Cephalalgia : an international journal of headache* 22, 384–394.
- 866 <https://doi.org/10.1046/J.1468-2982.2002.00382.X>
- 867 Mohkhedkar, M., Venigalla, S.S.K., Janakiraman, V., 2021. Autoantigens That May Explain
- 868 Postinfection Autoimmune Manifestations in Patients With Coronavirus Disease 2019 Displaying
- 869 Neurological Conditions. *The Journal of Infectious Diseases* 223, 536–537.
- 870 <https://doi.org/10.1093/INFDIS/JIAA703>
- 871 Nair, V.A., Raut, R. V., Prabhakaran, V., 2017. Investigating the Blood Oxygenation Level-Dependent
- 872 Functional MRI Response to a Verbal Fluency Task in Early Stroke before and after
- 873 Hemodynamic Scaling. *Frontiers in Neurology* 8, 283. <https://doi.org/10.3389/fneur.2017.00283>
- 874 Nasreddine, Z., Phillips, N., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J.,
- 875 Chertkow, H., 2005. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild
- 876 cognitive impairment. *Journal of the American Geriatrics Society* 53, 695–699.
- 877 <https://doi.org/10.1111/J.1532-5415.2005.53221.X>
- 878 Newcombe, V.F.J., Spindler, L.R.B., Das, T., Winzeck, S., Allinson, K., Stamatakis, E.A., Menon, D.K.,
- 879 2020. Neuroanatomical substrates of generalized brain dysfunction in COVID-19. *Intensive Care*
- 880 *Medicine* 2020 47:1 47, 116–118. <https://doi.org/10.1007/S00134-020-06241-W>
- 881 Nilsson, T., Longmore, J., Shaw, D., Jansen Olesen, I.J., Edvinsson, L., 1999. Contractile 5-HT1B
- 882 receptors in human cerebral arteries: pharmacological characterization and localization with
- 883 immunocytochemistry. *British Journal of Pharmacology* 128, 1133–1140.
- 884 <https://doi.org/10.1038/SJ.BJP.0702773>

- 885 Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008a. An R package to compute commonality
886 coefficients in the multiple regression case: An introduction to the package and a practical
887 example. *Behavior Research Methods* 40, 457–466. <https://doi.org/10.3758/BRM.40.2.457>
- 888 Nimon, K., Lewis, M., Kane, R., Haynes, R.M., 2008b. An R package to compute commonality
889 coefficients in the multiple regression case: An introduction to the package and a practical
890 example. *Behavior Research Methods* 40, 457–466. <https://doi.org/10.3758/BRM.40.2.457>
- 891 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su,
892 L., O'Brien, J.T., Rowe, J.B., 2019a. Neuroinflammation and functional connectivity in Alzheimer's
893 disease: interactive influences on cognitive performance. *The Journal of Neuroscience* 39, 2574–
894 18. <https://doi.org/10.1523/jneurosci.2574-18.2019>
- 895 Passamonti, L., Tsvetanov, K.A., Jones, P.S., Bevan-Jones, W.R., Arnold, R., Borchert, R.J., Mak, E., Su,
896 L., O'Brien, J.T., Rowe, J.B., 2019b. Neuroinflammation and Functional Connectivity in
897 Alzheimer's Disease: Interactive Influences on Cognitive Performance. *The Journal of*
898 *neuroscience : the official journal of the Society for Neuroscience* 39.
899 <https://doi.org/10.1523/JNEUROSCI.2574-18.2019>
- 900 Paterson, R., Brown, R., Benjamin, L., Nortley, R., S, W., T, B., DL, J., G, K., RE, R., L, Z., V, V., A, K., R, G.,
901 K, C., E, B., H, T., G, P., G, C., J, M., P, M., B, M., ST, L., PR, M., V, L., S, K., W, Y., SA, T., AJM, F., G,
902 H., TD, M., AD, E., C, C., NWS, D., M, Y., D, A., J, Sreedharan, E, S., JM, S., A, Chandratheva, RJ, P.,
903 R, S., A, Checkley, N, L., SF, F., F, C., C, Houlihan, M, T., MP, L., J, Spillane, R, H., A, V., DJ, W., C,
904 Hoskote, Jäger HR, Manji, H., Zandi, M., 2020. The emerging spectrum of COVID-19 neurology:
905 clinical, radiological and laboratory findings. *Brain : a journal of neurology* 143, 3104–3120.
906 <https://doi.org/10.1093/BRAIN/AWAA240>
- 907 PL, E., MA, M., V, B., RP, T., R, M., A, A., AB, N., 2003. The 6-min walk test: a quick measure of
908 functional status in elderly adults. *Chest* 123, 387–398.
909 <https://doi.org/10.1378/CHEST.123.2.387>
- 910 Pruim, R.H.R., Mennes, M., Buitelaar, J.K., Beckmann, C.F., 2015a. Evaluation of ICA-AROMA and
911 alternative strategies for motion artifact removal in resting state fMRI. *NeuroImage* 112, 278–
912 287. <https://doi.org/10.1016/j.neuroimage.2015.02.063>
- 913 Pruim, R.H.R., Mennes, M., van Rooij, D., Llera, A., Buitelaar, J.K., Beckmann, C.F., 2015b. ICA-AROMA:
914 A robust ICA-based strategy for removing motion artifacts from fMRI data. *NeuroImage* 112,
915 267–277. <https://doi.org/10.1016/j.neuroimage.2015.02.064>
- 916 Raut, R. V., Nair, V.A., Sattin, J.A., Prabhakaran, V., 2016. Hypercapnic evaluation of vascular reactivity
917 in healthy aging and acute stroke via functional MRI. *NeuroImage: Clinical* 12, 173–179.
918 <https://doi.org/10.1016/j.nicl.2016.06.016>

- 919 Rorden, C., Brett, M., 2000. Stereotaxic display of brain lesions. *Behavioural neurology* 12, 191–200.
920 <https://doi.org/10.1155/2000/421719>
- 921 Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Ring, P.B., Henriksen, O., 1996. Susceptibility
922 Contrast Imaging of CO₂-Induced Changes in the Blood Volume of the Human Brain. *Acta*
923 *Radiologica* 37, 813–822. <https://doi.org/10.3109/02841859609177722>
- 924 Rostrup, E., Larsson, H.B.W., Toft, P.B., Garde, K., Thomsen, C., Ring, P., Søndergaard, L., Henriksen,
925 O., 1994. Functional MRI of CO₂ induced increase in cerebral perfusion. *NMR in Biomedicine* 7,
926 29–34. <https://doi.org/10.1002/nbm.1940070106>
- 927 Satterthwaite, T.D., Elliott, M. a, Gerraty, R.T., Ruparel, K., Loughhead, J., Calkins, M.E., Eickhoff, S.B.,
928 Hakonarson, H., Gur, R.C.R.E., Gur, R.C.R.E., Wolf, D.H., 2013. An improved framework for
929 confound regression and filtering for control of motion artifact in the preprocessing of resting-
930 state functional connectivity data. *NeuroImage* 64, 240–56.
931 <https://doi.org/10.1016/j.neuroimage.2012.08.052>
- 932 Schnaubelt, S., Oppenauer, J., Tihanyi, D., Mueller, M., Maldonado-Gonzalez, E., Zejnilovic, S.,
933 Haslacher, H., Perkmann, T., Strassl, R., Anders, S., Stefenelli, T., Zehetmayer, S., Koppensteiner,
934 R., Domanovits, H., Schlager, O., 2021. Arterial stiffness in acute COVID-19 and potential
935 associations with clinical outcome. *Journal of internal medicine* 290, 437–443.
936 <https://doi.org/10.1111/JOIM.13275>
- 937 Shi, Y., Thrippleton, M.J., Makin, S.D., Marshall, I., Geerlings, M.I., de Craen, A.J.M., van Buchem, M.A.,
938 Wardlaw, J.M., 2016. Cerebral blood flow in small vessel disease: A systematic review and meta-
939 analysis. *Journal of cerebral blood flow and metabolism : official journal of the International*
940 *Society of Cerebral Blood Flow and Metabolism* 36, 1653–1667.
941 <https://doi.org/10.1177/0271678X16662891>
- 942 Sibille, E., Su, J., Leman, S., le Guisquet, A.M., Iburguen-Vargas, Y., Joeyen-Waldorf, J., Glorioso, C.,
943 Tseng, G.C., Pezzone, M., Hen, R., Belzung, C., 2007. Lack of serotonin1B receptor expression
944 leads to age-related motor dysfunction, early onset of brain molecular aging and reduced
945 longevity. *Molecular psychiatry* 12, 1042–1056. <https://doi.org/10.1038/SJ.MP.4001990>
- 946 Tsvetanov, K.A., Gazzina, S., Jones, P.S., Swieten, J., Borroni, B., Sanchez-Valle, R., Moreno, F., Laforce,
947 R., Graff, C., Synofzik, M., Galimberti, D., Masellis, M., Tartaglia, M.C., Finger, E., Vandenberghe,
948 R., Mendonça, A., Tagliavini, F., Santana, I., Ducharme, S., Butler, C., Gerhard, A., Danek, A.,
949 Levin, J., Otto, M., Frisoni, G., Ghidoni, R., Sorbi, S., Rohrer, J.D., Rowe, J.B., 2020a. Brain
950 functional network integrity sustains cognitive function despite atrophy in presymptomatic
951 genetic frontotemporal dementia. *Alzheimer's & Dementia* alz.12209.
952 <https://doi.org/10.1002/alz.12209>

- 953 Tsvetanov, K.A., Henson, R.N.A., Jones, P.S., Mutsaerts, H., Fuhrmann, D., Tyler, L.K., Rowe, J.B.,
954 2020b. The effects of age on resting-state BOLD signal variability is explained by cardiovascular
955 and cerebrovascular factors, in: *Psychophysiology*. Blackwell Publishing Inc.
956 <https://doi.org/10.1111/psyp.13714>
- 957 Tsvetanov, K.A., Henson, R.N.A., Rowe, J.B., 2020c. Separating vascular and neuronal effects of age on
958 fMRI BOLD signals. *Philosophical Transactions of the Royal Society B: Biological Sciences*.
959 <https://doi.org/10.1098/rstb.2019.0631>
- 960 Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Davis, S.W., Shafto, M.A., Taylor, J.R., Williams, N., Rowe,
961 J.B., 2015. The effect of ageing on fMRI: Correction for the confounding effects of vascular
962 reactivity evaluated by joint fMRI and MEG in 335 adults. *Human Brain Mapping* 36, 2248–2269.
963 <https://doi.org/10.1002/hbm.22768>
- 964 Tsvetanov, K.A., Henson, R.N.A., Tyler, L.K., Razi, A., Geerligs, L., Ham, T.E., Rowe, J.B., 2016. Extrinsic
965 and intrinsic brain network connectivity maintains cognition across the lifespan despite
966 accelerated decay of regional brain activation. *Journal of Neuroscience* 36, 3115–26.
967 <https://doi.org/10.1523/JNEUROSCI.2733-15.2016>
- 968 Tsvetanov, K.A., Ye, Z., Hughes, L., Samu, D., Treder, M.S., Wolpe, N., Tyler, L.K., Rowe, J.B., for
969 Cambridge Centre for Ageing and Neuroscience, 2018. Activity and connectivity differences
970 underlying inhibitory control across the adult lifespan. *The Journal of neuroscience : the official*
971 *journal of the Society for Neuroscience* 38, 7887–7900.
972 <https://doi.org/10.1523/JNEUROSCI.2919-17.2018>
- 973 Ulhaq, Z.S., Soraya, G.V., 2020. Interleukin-6 as a potential biomarker of COVID-19 progression.
974 *Médecine et Maladies Infectieuses* 50, 382–383.
975 <https://doi.org/10.1016/J.MEDMAL.2020.04.002>
- 976 Vaishnavi, S.N., Vlassenko, A.G., Rundle, M.M., Snyder, A.Z., Mintun, M.A., Raichle, M.E., 2010.
977 Regional aerobic glycolysis in the human brain. *Proceedings of the National Academy of Sciences*
978 *of the United States of America* 107, 17757–17762.
979 <https://doi.org/10.1073/PNAS.1010459107/-/DCSUPPLEMENTAL>
- 980 Váša, F., Seidlitz, J., Romero-Garcia, R., Whitaker, K.J., Rosenthal, G., Vértes, P.E., Shinn, M.,
981 Alexander-Bloch, A., Fonagy, P., Dolan, R.J., Jones, P.B., Goodyer, I.M., Sporns, O., Bullmore, E.T.,
982 2018. Adolescent Tuning of Association Cortex in Human Structural Brain Networks. *Cerebral*
983 *cortex (New York, N.Y. : 1991)* 28, 281–294. <https://doi.org/10.1093/CERCOR/BHX249>
- 984 Verity, R., Okell, L.C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G.,
985 Thompson, H., Walker, P.G.T., Fu, H., Dighe, A., Griffin, J.T., Baguelin, M., Bhatia, S., Boonyasiri,
986 A., Cori, A., Cucunubá, Z., FitzJohn, R., Gaythorpe, K., Green, W., Hamlet, A., Hinsley, W., Laydon,

- 987 D., Nedjati-Gilani, G., Riley, S., van Elsland, S., Volz, E., Wang, H., Wang, Y., Xi, X., Donnelly, C.A.,
988 Ghani, A.C., Ferguson, N.M., 2020. Estimates of the severity of coronavirus disease 2019: a
989 model-based analysis. *The Lancet Infectious Diseases* 20, 669–677.
990 [https://doi.org/10.1016/S1473-3099\(20\)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-](https://doi.org/10.1016/S1473-3099(20)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-FC2C52BBAFD7/MMC1.PDF)
991 [FC2C52BBAFD7/MMC1.PDF](https://doi.org/10.1016/S1473-3099(20)30243-7/ATTACHMENT/E32585C1-0F24-46F4-855E-FC2C52BBAFD7/MMC1.PDF)
- 992 Vestergaard, M.B., Jensen, M.L.F., Arnglim, N., Lindberg, U., Larsson, H.B.W., 2020. Higher
993 physiological vulnerability to hypoxic exposure with advancing age in the human brain. *Journal*
994 *of Cerebral Blood Flow & Metabolism* 40, 341. <https://doi.org/10.1177/0271678X18818291>
- 995 Vlassenko, A.G., Vaishnavi, S.N., Couture, L., Sacco, D., Shannon, B.J., Mach, R.H., Morris, J.C., Raichle,
996 M.E., Mintun, M.A., 2010. Spatial correlation between brain aerobic glycolysis and amyloid- β (A β
997) deposition. *Proceedings of the National Academy of Sciences of the United States of America*
998 107, 17763–17767. <https://doi.org/10.1073/PNAS.1010461107>
- 999 Vos de Wael, R., Benkarim, O., Paquola, C., Lariviere, S., Royer, J., Tavakol, S., Xu, T., Hong, S.J., Langs,
1000 G., Valk, S., Mistic, B., Milham, M., Margulies, D., Smallwood, J., Bernhardt, B.C., 2020.
1001 BrainSpace: a toolbox for the analysis of macroscale gradients in neuroimaging and
1002 connectomics datasets. *Communications Biology* 2020 3:1 3, 1–10.
1003 <https://doi.org/10.1038/s42003-020-0794-7>
- 1004 Wagerle, L.C., Mishra, O.P., 1988. Mechanism of CO₂ response in cerebral arteries of the newborn
1005 pig: Role of phospholipase, cyclooxygenase, and lipoxygenase pathways. *Circulation Research*
1006 62, 1019–1026. <https://doi.org/10.1161/01.RES.62.5.1019>
- 1007 Willie, C.K., Tzeng, Y.-C., Fisher, J.A., Ainslie, P.N., 2014. Integrative regulation of human brain blood
1008 flow. *The Journal of physiology* 592, 841–59. <https://doi.org/10.1113/jphysiol.2013.268953>
- 1009 Wool, G.D., Miller, J.L., 2021. The Impact of COVID-19 Disease on Platelets and Coagulation.
1010 *Pathobiology* 88, 15–27. <https://doi.org/10.1159/000512007>
- 1011 Wu, S., Tyler, L.K., Rowe, J.B., Cam-CAN, Tsvetanov, K.A., 2021. Brain cerebral blood flow explains
1012 behaviour-relevant BOLD responses in fluid ability across the lifespan. In Preparation.
- 1013 Xu, L., Groth, K.M., Pearlson, G., Schretlen, D.J., Calhoun, V.D., 2009. Source-based morphometry: the
1014 use of independent component analysis to identify gray matter differences with application to
1015 schizophrenia. *Human brain mapping* 30, 711–24. <https://doi.org/10.1002/hbm.20540>
- 1016 Yang, A.C., Vest, R.T., Kern, F., Lee, D.P., Maat, C.A., Losada, P.M., Chen, M.B., Agam, M., Schaum, N.,
1017 Khoury, N., Calcuttawala, K., Pálovics, R., Shin, A., Wang, E.Y., Luo, J., Gate, D., Siegenthaler, J.A.,
1018 McNERNEY, M.W., Keller, A., Wyss-Coray, T., 2021. A human brain vascular atlas reveals diverse
1019 cell mediators of Alzheimer’s disease risk. *bioRxiv* 2021.04.26.441262.
1020 <https://doi.org/10.1101/2021.04.26.441262>

- 1021 Zhang, X.J., Qin, J.J., Cheng, X., Shen, L., Zhao, Y.C., Yuan, Y., Lei, F., Chen, M.M., Yang, H., Bai, L., Song,
1022 X., Lin, L., Xia, M., Zhou, F., Zhou, J., She, Z.G., Zhu, L., Ma, X., Xu, Q., Ye, P., Chen, G., Liu, L., Mao,
1023 W., Yan, Y., Xiao, B., Lu, Z., Peng, G., Liu, M., Yang, Jun, Yang, L., Zhang, C., Lu, H., Xia, X., Wang,
1024 D., Liao, X., Wei, X., Zhang, B.H., Zhang, X., Yang, Juan, Zhao, G.N., Zhang, P., Liu, P.P., Loomba,
1025 R., Ji, Y.X., Xia, J., Wang, Y., Cai, J., Guo, J., Li, H., 2020. In-Hospital Use of Statins Is Associated
1026 with a Reduced Risk of Mortality among Individuals with COVID-19. *Cell metabolism* 32, 176-
1027 187.e4. <https://doi.org/10.1016/J.CMET.2020.06.015>
- 1028 Zubair, A.S., McAlpine, L.S., Gardin, T., Farhadian, S., Kuruvilla, D.E., Spudich, S., 2020.
1029 Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of
1030 Coronavirus Disease 2019: A Review. *JAMA Neurology* 77, 1018–1027.
1031 <https://doi.org/10.1001/JAMANEUROL.2020.2065>
- 1032